Cyclerion Therapeutics, Inc. — fact timeline

Cyclerion Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with Korsana Biosciences, Inc. (effective 2026-04-01).

“On April 1, 2026, Cyclerion Therapeutics, Inc., a Massachusetts corporation (“ Cyclerion ”), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Cyclerion (“ First Merger Sub ”), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Cyclerion (“ Second Merger Sub ” and, together with First Merger Sub, “ Merger Sub ”), and Korsana Biosciences, Inc., a Delaware corporation (“ Korsana ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”)”

Cyclerion Therapeutics, Inc. entered into Collaboration and Option Agreement with Medsteer, SAS valued at up to $3.7 million (effective 2026-01-03).

“On January 3, 2026, Cyclerion Therapeutics, Inc. (the “Company”) and the Medsteer, SAS (“Medsteer”) entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer”

Peter Hecht resigned as President and Chief Executive Officer at Cyclerion Therapeutics, Inc..

“She replaces Peter Hecht, Ph.D., who resigned on November 30, 2023 as President and Chief Executive Officer to pursue his responsibilities as President of Tisento.”

Regina Graul was elected as President at Cyclerion Therapeutics, Inc..

“On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) unanimously elected Regina Graul Ph.D., as President of the Company, effective December 1, 2023.”

Dina Katabi was elected as Director at Cyclerion Therapeutics, Inc..

“On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.”

Michael Higgins was elected as Director at Cyclerion Therapeutics, Inc..

“On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.”

Ole Isacson resigned as director at Cyclerion Therapeutics, Inc..

“On November 19, 2023, Ole Isacson, M.D., Ph.D., tendered his resignation as a director of Cyclerion Therapeutics, Inc. (the “Company”), effective immediately.”

Anjeza Gjino resigned as Chief Financial Officer at Cyclerion Therapeutics, Inc..

“On October 17, 2023, Cyclerion Therapeutics Inc. (“Cyclerion”) and Anjeza Gjino (“Ms. Gjino”), Cyclerion’s Chief Financial Officer, entered into a Separation and Release of Claims Agreement, dated such date (the “Agreement”), pursuant to which Ms. Gjino will resign from Cyclerion.”

Cyclerion Therapeutics, Inc. shareholders approved Approval of issuance of shares of Common Stock upon conversion of Series A Convertible Preferred Stock to comply with Nasdaq Listing Rules (Nasdaq Proposal) at the 2023-07-19 meeting.

“Proposal 2: The Nasdaq Proposal A proposal to approve, for purposes of complying with the Nasdaq Listing Rules, the issuance of shares of Common Stock upon potential conversion of the shares of Cyclerion Preferred Stock issued to Dr. Hecht pursuant to the terms of the Stock Purchase Agreement, to the extent that following such conversion Dr. Hecht would hold 20% or more of the outstanding shares of Common Stock, as further described in the Proxy Statement. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s shareholders: For Against Abstentions Broker Non-Votes 1,449,712 65,191 1,026 0”

Cyclerion Therapeutics, Inc. shareholders approved Approval and adoption of the Asset Purchase Agreement and the transactions contemplated thereby (Asset Sale Proposal) at the 2023-07-19 meeting.

“Proposal 1: The Asset Sale Proposal A proposal to approve and adopt the Asset Purchase Agreement and the transactions contemplated thereby, as further described in the Proxy Statement . The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s shareholders: For Against Abstentions Broker Non-Votes 1,440,138 74,742 1,049 0”

Cheryl Gault resigned as Chief Operating Officer at Cyclerion Therapeutics, Inc..

“On June 26, 2023, Cheryl Gault announced her resignation as the Chief Operating Officer of Cyclerion Therapeutics, Inc.”

Cyclerion Therapeutics, Inc.: Filed Articles of Amendment to designate Series A Preferred Stock (effective 2023-05-19).

“On May 19, 2023 , the Company filed with the Secretary of the Commonwealth of the Commonwealth of Massachusetts Articles of Amendment (the “Articles of Amendment”) to the Company’s Restated Articles of Organization, as amended, designating shares of the Series A Preferred Stock.”

Cyclerion Therapeutics, Inc.: Effected a 1-for-20 reverse stock split of common stock via Articles of Amendment to the Restated Articles of Organization (effective 2023-05-15).

“On May 15, 2023, Cyclerion Therapeutics, Inc. (the “Company”) filed Articles of Amendment to the Company’s Restated Articles of Organization (the “Articles of Amendment”) with the Secretary of the Commonwealth of the Commonwealth of Massachusetts to effect a 1-for-20 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, no par value (the “Common Stock”), at 5:00 p.m. Eastern Time on that date (the “Effective Time”).”

Cyclerion Therapeutics, Inc. shareholders approved Proposal to grant the Board discretional authority to effect a reverse stock split at the 2023-05-15 meeting.

“3. Proposal to grant the Board discretional authority to effect a reverse stock split: For Against Abstain 29,493,422 2,912,129 45,310”

Cyclerion Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-15 meeting.

“2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain 32,100,837 309,269 40,755”

Cyclerion Therapeutics, Inc. shareholders approved Election of Directors at the 2023-05-15 meeting.

“At the Company’s annual meeting of stockholders held on May 15, 2023, as contemplated by the Company’s definitive proxy material for the meeting, certain matters were submitted to a vote of stockholders. The following tables summarize the results of voting with respect to each matter: 1. Election of Directors: For Against Abstain Broker Non-Votes Errol De Souza, Ph.D. 24,043,739 482,205 95,703 7,829,214 Peter M. Hecht, Ph.D. 22,832,872 1,729,771 59,004 7,829,214 Steven Hyman, M.D. 24,124,609 418,935 78,103 7,829,214 Ole Isacson, M.D., Ph.D. 24,121,645 409,714 90,288 7,829,214 Terrance McGuire 18,940,792 5,607,350 73,505 7,829,214”

Cyclerion Therapeutics, Inc. reported financial results for first quarter 2023.

“Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.”

Cyclerion Therapeutics, Inc. reported the full year 2022 results: net income approximately $44.1 million.

“Net loss was approximately $44.1 million for the full year 2022, as compared to $51.6 million for the full year 2021.”

Cyclerion Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na”

Andreas Busch, Ph.D. resigned as Chief Scientific Officer at Cyclerion Therapeutics, Inc..

“On and effective September 30, 2022, Andreas Busch, Ph.D. resigned from his position as Chief Scientific Officer of Cyclerion Therapeutics, Inc. (the “Company”) to pursue another opportunity.”

Steven E. Hyman, M.D. was appointed as director at Cyclerion Therapeutics, Inc..

“Cyclerion Therapeutics, Inc. (the “Company”) has announced that Steven E. Hyman, M.D., was appointed to the Company’s board of directors (the “Board”) on July 25, 2022.”

Peter M. Hecht was appointed as Interim Chief Financial Officer at Cyclerion Therapeutics, Inc..

“On October 27, 2021, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) temporarily appointed Peter M. Hecht, Ph.D., as Interim Chief Financial Officer (principal financial and accounting officer) of the Company while Anjeza Gjino is on maternity leave.”

Kevin B. Churchwell, M.D. resigned as Director at Cyclerion Therapeutics, Inc..

“On and effective August 18, 2021, Kevin B. Churchwell, M.D., resigned from the board of directors of Cyclerion Therapeutics, Inc.”